 |
|
 |
Skin |
|
|
Pipeline Insight: Orphan Diseases in CNS - Part I: Huntington's Disease
Publication Date November 2007
Publisher Datamonitor
Product Type Report
Pages 94
ISBN Number not applicable
Product Code DAT1259
|
|
|
Summary
Introduction
The current Huntington's disease market is comprised of off-label prescriptions of psychotropic drugs. In the near term, two pipeline drugs are set to enter the market, demonstrating the viability of this disease as a primary marketing indication. In the longer term, with a strong genetic link and reliable diagnostic test, prophylactic treatment with a disease modifying drug could prove lucrative.
Scope
- Scenario based analysis and forecasts of the commercial potential of the Huntington's disease market to 2016.
- Analysis of patient potential, marketing factors, commercial attractiveness and clinical attractiveness of key late-stage pipeline drugs.
- Strategic recommendations for maximizing the potential of drugs in this niche orphan disease market.
- Indication-specific sales forecasts of key pipeline drugs to 2016.
Highlights
NeuroSearch's ACR16 is set to become the market leader by 2010. Targeting a broad spectrum of symptoms, and possessing a novel mode of action, neurologists are likely to view this drug favorably when compared to current treatments.
The launch of Xenazine (tetrabenazine) on the US market and further roll-out across the 5EU looks set to be a good strategic move by Prestwick Pharmaceuticals and Cambridge Laboratories. However, peak market penetration is limited by the drug's use predominantly in severe patients and its poor side-effect profile.
Forecasts based on various potential patient population sizes and drug prices, identify several scenarios in which blockbuster drugs could be established in this market. A theoretical drug which could achieve this is defined.
Reasons to Purchase
- Access the lucrative potential of this underdeveloped neurodegenerative disease therapeutic market.
- Benchmark key late-stage compounds against current leading therapies and a theoretical "ideal" treatment.
- Understand the opportunities in this market based on the comments of interviewed key opinion leaders and industry executives.
|
Content
- About Datamonitor Healthcare
- About The Cns Pharmaceutical Analysis Team
- Chapter 1 Executive Summary
- Scope Of The Analysis
- Contributing Experts
- Interviewed Key Opinion Leaders
- Datamonitor Insight Into The Huntington's Disease Market
- Key Metrics
- Datamonitor Pipeline Assessment Summary
- Related Reports
- Upcoming Reports
- Chapter 2 Market Overview
- Definition Of Huntington's Disease
- Current Market Overview
- Current Therapies Are Limited To Managing The Symptoms Associated With Hd And Co-Morbidities
- No Treatment Proven To Alter The Course Of The Disease
- Current Treatment Classes
- Current Market Value And Trends
- Antipsychotics And Monoamine-Depleting Agents
- Antidepressants And Anxiolytics
- Anti-Parkinsonism Drugs
- Etiology Of Huntington's Disease
- Risk Of Inheriting Hd
- Prognosis For Hd Patients
- Epidemiology Of Huntington's Disease
- Base Scenario
- High Prevalence Rate Patient Population Scenario
- Very Low Prevalence In Japan
- Increasing Future Trend In Patient Population
- Unmet Need In Huntington's Disease
- Slowing The Progression Of The Disease
- Reduced Movement Disorders
- Reduced Depression, Anxiety And Psychosis
- Chapter 3 Future Market Potential
- Future Market Scenarios For Symptomatic Patients
- Base Prevalence Future Market Value Forecast
- High Prevalence Future Market Value
- Price Of Future Hd Drugs
- Current Cost Of Cns Drugs Comparable To A New Disease Modifying Hd Therapy
- Theoretical Disease Modifying Drug
- Pre-Symptomatic "At Risk" Population - The Lucrative Untapped Market
- Scenarios Matrix Summary
- Chapter 4 Pipeline Overview And Dynamics
- Pipeline Drugs Market Potential
- Pipeline Overview
- Definition Of Current Comparator Therapy
- Classification Of Pipeline Products
- Recently Discontinued Or Failed Projects
- Chapter 5 Late-Stage Drug Analysis & Forecasts
- Xenazine (Tetrabenazine)
- Drug Overview
- Forecasts To 2016
- Datamonitor Drug Assessment Summary
- Marketing Factors
- Market Penetration
- Xenazine Pricing Assumptions
- Patient Potential
- Satisfaction Of Unmet Needs
- Clinical Trial Data
- Tetrabenazine As Antichorea Therapy In Huntington's Disease, Phase Iii Study
- Phase Iii Extension Study
- Older Studies Investigating Tetrabenazine In Hd
- Acr16
- Drug Overview
- Forecasts To 2016
- Datamonitor Drug Assessment Summary
- Marketing Factors
- Market Penetration
- Neurosearch Should Concentrate Marketing Efforts On The Motor Dysfunction Benefits Of Acr16
- Acr16 Pricing Assumptions
- Patient Potential
- The Patient Potential Of Treating Depression
- Positive Effects On Psychosis And Agitation May Also Be Seen In Larger-Scale Trials
- Even If Chorea Is Not Adequately Treated With Acr16, The Patient Potential Would Be High
- Significant Alleviation Of Chorea May Still Be Shown In Larger-Scale Clinical Trials
- Satisfaction Of Unmet Needs
- Clinical Trial Data
- Planned Phase Iii Trials
- Phase Ii Study: Acr16c007
- Pre-Clinical Data - What Is A Dopamine Stabilizer?
- Hd-02 - Ultra-Pure Creatine
- Drug Overview
- Forecasts To 2016
- Marketing Factors
- Patient Potential
- Satisfaction Of Unmet Needs
- Clinical Trial Data
- Planned Phase Iii Trial
- Phase I/Ii Study
- Independent Study On Creatine
- Dimebon
- Drug Overview
- Forecasts To 2016
- Clinical Trial Data
- Ongoing Phase Ii Trial
- Completed Phase I Study
- Further Development And Submission
- Bibliography
- Appendix A
- Methodology
- Datamonitor Forecast Methodology For The Hd Market
- Epidemiology Forecasts
- Product Forecasts
- Definition Of A Standard Unit
- Contributing Experts
- Interviewed Neurosearch Company Executives
- Appendix B
- About Datamonitor
- About Datamonitor Healthcare
- Datamonitor Healthcare's Therapy Area Capabilities
- About The Disease Analysis Team
- Disclaimer
- List Of Tables
- Table 1: Hd Base Scenario Prevalence And Patient Population In The 6mm, 2007
- Table 2: Hd High Prevalence Scenario Patient Population In The 6mm, 2007
- Table 3: Hd Prevalence And Patient Population In Japan, 2007
- Table 4: Price Of Comparable Cns Drugs, 2007
- Table 5: Matrix Of Hd Market Value Dependent On Patient Population And Price In The 6mm, 2007
- Table 6: R&D Clinical-Stage Pipeline In Huntington's Disease, 2007
- Table 7: Xenazine Key Assumptions And Events, 2007
- Table 8: Key Clinical And Commercial Attractiveness Factors For Xenazine
- Table 9: Acr16 Key Assumptions And Events, 2007
- Table 10: Key Clinical/Commercial Attractiveness Factors For Acr16
- Table 11: Datamonitor Drug Assessment Parameters
- List Of Figures
- Figure 1: Forecast Of Total 6mm Market Size And Key Pipeline Drugs, 2004-2016,
- Figure 2: Drug Assessment Summary For Hd Treatments, 2007
- Figure 3: Total Sales Revenue Of The Six Major Hd Markets By Region, 2003-07
- Figure 4: Total Sales Revenue Of The Six Major Hd Markets By Drug Class, 2003-07
- Figure 5: Proportion Of Hd-Specific Sales Revenue Attributed To Atypical Versus Typical Antipsychotics In The Us, 2004 And 2006
- Figure 6: Proportion Of Hd-Specific Sales Revenue Attributed To Atypical Versus Typical Antipsychotics In The 5eu, 2004 And 2006
- Figure 7: Genetic Risk Of Developing Hd
- Figure 8: Unmet Needs In Hd Treatment, 2007
- Figure 9: Base Prevalence Future Market Value For Hd ($M), Historical Sales 2004-06, Forecast Sales, 2007-2016, 6mm
- Figure 10: High Hd Prevalence Scenario Future Market Value For Hd ($M), Historical Sales 2004-06, Forecast Sales, 2007-2016, 6mm
- Figure 11: Potential Total Hd Market Value ($M), 2004-2016
- Figure 12: Drug Assessment Summary For Theoretical Drug X For The Treatment Of Hd, 2007
- Figure 13: Summary Of Hd Market And Pipeline Drugs Potential ($M), Historical Sales 2004-06, Forecast Sales, 2007-2016
- Figure 14: Xenazine Hd Specific Sales Revenue Forecast ($M), Historical Sales 2004-06, Forecast Sales 2007-2016
- Figure 15: Drug Assessment Summary For Xenazine In Hd, 2007
- Figure 16: Acr16 Hd-Specific Sales Revenue Forecast ($M), Historical Sales 2004-06, Forecast Sales, 2007-2016
- Figure 17: Drug Assessment Summary For Acr16 In Hd, 2007
|
|
|
